Beran M - Search Results

1

CI-973, a new platinum derivative with potential antileukemic activity.

O'Brien S, Kantarjian H, Freireich E, Johnston D, Nguyen K, Beran M. O'Brien S, et al. Among authors: beran m. Cancer Res. 1992 Aug 1;52(15):4130-4. Cancer Res. 1992. PMID: 1638526

2

Resistance to 4-(9-acridinylamino) methanesulphon-m-anisidide (m-AMSA) in human myeloid leukaemia.

Skinner WL, Murray D, Kohli V, Beran M, McCredie KB, Freireich EJ, Andersson BS. Skinner WL, et al. Among authors: beran m. Br J Cancer. 1990 Jan;61(1):51-5. doi: 10.1038/bjc.1990.11. Br J Cancer. 1990. PMID: 2297490 Free PMC article.

3

Biological properties and growth in SCID mice of a new myelogenous leukemia cell line (KBM-5) derived from chronic myelogenous leukemia cells in the blastic phase.

Beran M, Pisa P, O'Brien S, Kurzrock R, Siciliano M, Cork A, Andersson BS, Kohli V, Kantarjian H. Beran M, et al. Cancer Res. 1993 Aug 1;53(15):3603-10. Cancer Res. 1993. PMID: 8339266

4

Fludarabine and cytosine arabinoside in the treatment of refractory or relapsed acute lymphocytic leukemia.

Suki S, Kantarjian H, Gandhi V, Estey E, O'Brien S, Beran M, Rios MB, Plunkett W, Keating M. Suki S, et al. Among authors: beran m. Cancer. 1993 Oct 1;72(7):2155-60. doi: 10.1002/1097-0142(19931001)72:7<2155::aid-cncr2820720715>3.0.co;2-v. Cancer. 1993. PMID: 8374873 Clinical Trial.

5

Antisense RNA inhibition of phosphoprotein p18 expression abrogates the transformed phenotype of leukemic cells.

Jeha S, Luo XN, Beran M, Kantarjian H, Atweh GF. Jeha S, et al. Among authors: beran m. Cancer Res. 1996 Mar 15;56(6):1445-50. Cancer Res. 1996. PMID: 8640838

6

Evaluation of CI-973, a platinum analogue, in refractory or relapsed acute leukemia.

Kantarjian HM, Beran M, O'Brien S, Robertson L, Siddik Z, Yoshida M, Yang LY, Rios MB, Keating MJ, Meyer M, et al. Kantarjian HM, et al. Among authors: beran m. Leukemia. 1996 Mar;10(3):396-401. Leukemia. 1996. PMID: 8642853 Clinical Trial.

7

Selective inhibition of cell proliferation and BCR-ABL phosphorylation in acute lymphoblastic leukemia cells expressing Mr 190,000 BCR-ABL protein by a tyrosine kinase inhibitor (CGP-57148).

Beran M, Cao X, Estrov Z, Jeha S, Jin G, O'Brien S, Talpaz M, Arlinghaus RB, Lydon NB, Kantarjian H. Beran M, et al. Clin Cancer Res. 1998 Jul;4(7):1661-72. Clin Cancer Res. 1998. PMID: 9676840

8

Tallimustine, an effective antileukemic agent in a severe combined immunodeficient mouse model of adult myelogenous leukemia, induces remissions in a phase I study.

Beran M, Jeha S, O'Brien S, Estey E, Vitek L, Zurlo MG, Rios MB, Keating M, Kantarjian H. Beran M, et al. Clin Cancer Res. 1997 Dec;3(12 Pt 1):2377-84. Clin Cancer Res. 1997. PMID: 9815637 Clinical Trial.

9

High levels of vascular endothelial growth factor receptor-2 correlate with shortened survival in chronic lymphocytic leukemia.

Ferrajoli A, Manshouri T, Estrov Z, Keating MJ, O'Brien S, Lerner S, Beran M, Kantarjian HM, Freireich EJ, Albitar M. Ferrajoli A, et al. Among authors: beran m. Clin Cancer Res. 2001 Apr;7(4):795-9. Clin Cancer Res. 2001. PMID: 11309324

10

Mitoxantrone and high-dose etoposide for patients with relapsed or refractory acute leukemia.

O'Brien S, Kantarjian H, Estey E, Koller C, Beran M, McCredie K, Keating M. O'Brien S, et al. Among authors: beran m. Cancer. 1991 Aug 15;68(4):691-4. doi: 10.1002/1097-0142(19910815)68:4<691::aid-cncr2820680404>3.0.co;2-z. Cancer. 1991. PMID: 1855168

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

615 results

Search Page

Filters